HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73834 | (Rac)-Arnebin 1 ((Rac)-β,β-Dimethylacrylalkannin; (Rac)-β,β-Dimethylacrylshikonin) | 5162-01-6 | (Rac)-Arnebin 1 ((Rac)-β,β-Dimethylacrylalkannin) is the racemate of β,β-Dimethylacrylalkannin and/or β,β-Dimethylacrylshikonin. |
|
V3952 | 1,4-DPCA | 331830-20-7 | 1,4-DPCA is a novel, potent and competitive inhibitor of prolyl 4-hydroxylase with IC50 value of 3.6 μM. |
|
V51644 | 1,4-DPCA ethyl ester | 86443-19-8 | 1,4-DPCA ethyl ester is the ethyl ester form of 1,4-DPCA and can inhibit FIH. |
|
V51634 | Steppogenin | 56486-94-3 | Steppogenin is a potent HIF-1α and DLL4 replacement with IC50s of 0.56 and 8.46 μM, respectively. |
|
V85084 | 5,3',4',3'',4'',5''-6-O-Ethyl-EGCG | 1613308-63-6 | |
|
V51627 | 7-Hydroxyneolamellarin A | 959662-26-1 | 7-Hydroxyneolamellarin A is a naturally occurring compound that can be found in the sponge Dendrilla nigra. |
|
V10310 | Adaptaquin | 385786-48-1 | Adaptaquin is a novel and potent hydroxyquinoline inhibitor of HIF-PHD (hypoxia-inducible factor prolyl hydroxylase 2) with an IC50 of 2 μM. |
|
V86307 | AFP464 dihydrochloride (NSC710464 dihydrochloride) | ||
|
V87508 | AJM 290 | 840474-95-5 | AJM 290 is a Trx-1 inhibitor. |
|
V51635 | Angiogenesis agent 1 | 2765218-28-6 | Angiogenic agent 1 (compound C-31) is a glycoside analog of a Rhodiola rosean analogue. |
|
V87491 | Anti-inflammatory agent 79 | Anti-inflammatory agent 79 (compound 17q) is an isoquinolinone derivative-based HIF-1 inhibitor (IC50: 0.55 μM), which can effectively block HIF-1 signaling and increase HIF-1α degradation. | |
|
V96811 | Antiproliferative agent-57 | Antiproliferative agent-57 (Compound M2) is a tumor angiogenesis inhibitor. | |
|
V86107 | Arylsulfonamide 64B (HIF inhibitor 64B) | 1342890-83-8 | |
|
V78298 | Axl-IN-16 | Axl-IN-16 is a dual (bifunctional) inhibitor of Axl and HIF. | |
|
V99680 | Casdatifan | 2709069-30-5 | Casdatifan (AB521) is an oral HIF-2α (hypoxia-inducible factor 2α) inhibitor. |
|
V87498 | Cyclo(CKLIIF) TFA | Cyclo CKLIIF is a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2, disrupts the interaction of HIF1-α and HIF2-α with HIF1-β, and has KD of 2.6 and 2.2 μM for the PAS-B domains of HIF1-α and HIF2-α, respectively. | |
|
V87488 | cyclo(CLLFVY) | 1446322-73-1 | cyclo(CLLFVY) is an inhibitor of hypoxia-inducible factor-1 (HIF-1) with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). |
|
V87494 | Cyclo(CRLLIF) | Cyclo CRLLIF is a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2, disrupts the interaction of HIF1-α and HIF2-α with HIF1-β, and has KD of 14.5 and 10.2 μM for the PAS-B domains of HIF1-α and HIF2-α, respectively. | |
|
V87503 | Cyclo(CRVIIF) | Cyclo CRVIIF is a dual inhibitor of hypoxia-inducible factors HIF1 and HIF2, disrupts the interaction of HIF1-α and HIF2-α with HIF1-β, and has KD of 65 and 123 μM for the PAS-B domains of HIF1-α and HIF2-α, respectively. | |
|
V87502 | D-01 | D-01 is a dual-targeted HIF-1α and EZH2 inhibitor (IC50 of 4.86 μM and 0.99 μM, respectively). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
